Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Saved in:
| Title: | Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts. |
|---|---|
| Authors: | Ricci, Francesca1, Guffanti, Federica1, Damia, Giovanna1 damia@marionegri.it, Broggini, Massimo1 |
| Source: | Molecular Cancer. 5/30/2017, Vol. 16, p1-6. 6p. 2 Charts, 3 Graphs. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
